Guggenheim Maintains Buy on Elevance Health, Raises Price Target to $485
Benzinga Newsdesk 1 week ago
Analyst RatingsNewsPrice TargetHot
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.
Guggenheim analyst Jason Cassorla maintains Elevance Health (NYSE:ELV) with a Buy and raises the price target from $460 to $485.